Nvidia’s results, Indian tariffs, French markets - what’s moving markets
Investing.com - D. Boral (OTC:BOALY) Capital raised its price target on NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to $34.00 from $31.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for NRXP range from $21.00 to $46.00, with the stock currently trading at $2.53.
The price target increase reflects an updated model with an elevated probability of success for the company’s ketamine-based therapy, NRX-100, from 70% to 80%.
D. Boral Capital cited the FDA’s expanded Fast Track designation covering all forms of suicidal depression as the key factor behind the adjustment.
The expanded designation strengthens both the regulatory case and commercial positioning for NRx Pharmaceuticals’ program, according to the research firm.
NRX-100 is NRx Pharmaceuticals’ ketamine-based therapy currently in development for treatment of suicidal depression.
In other recent news, NRX Pharmaceuticals reported its financial results for the second quarter of 2025, revealing a larger-than-anticipated loss. The company posted earnings per share of -$0.98, which was significantly below the projected -$0.53, marking an EPS surprise of 84.91%. This development was discussed in a recent earnings call, where the company’s financial performance and strategic plans were reviewed. The report highlights the challenges NRX Pharmaceuticals faces in meeting earnings expectations. Investors are likely to scrutinize the company’s future strategies and financial health closely. Further updates on the company’s plans and performance are anticipated in the upcoming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.